Drug intelligence / Profile preview

Sipimo

Development stage: Unknown
Lead developer: Shanghai Saibiman Biotechnology

Overview

Sipimo is a drug being investigated for its potential to delay cognitive impairment in patients with Alzheimer's Disease. It is referred to as an "essence liquid" and is currently undergoing a randomized, double-blind clinical trial. The drug is associated with Lianyungang Shibiman Biotechnology Co., Ltd.

Brand names: Sibipo essence liquid诗碧曼精华液

Beyond the preview

Go deeper on Sipimo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sipimo.

Explore the full profile